E-hospital: Fully coordinated cancer care and research in Europe

ESMO Highlights: Breast cancer

Combination of capecitabine and bevacizumab improves progression-free survival in metastatic breast cancer

Research shows chemotherapy has no negative effects on babies in utero

Importance of gynaecological surgeons and multidisciplinary strategies in advanced ovarian cancer

Cancer care in developing countries

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Nivolumab potentially superior to standard chemo in advanced melanoma

PD-L1 protein a possible immunotherapy target in mesothelioma

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer